| Title |
Conflict of Interest and the CREATE-X Trial in the New England Journal of Medicine
|
|---|---|
| Published in |
Science and Engineering Ethics, September 2017
|
| DOI | 10.1007/s11948-017-9966-3 |
| Pubmed ID | |
| Authors |
Akihiko Ozaki |
| Abstract |
There is an increasing emphasis on clear disclosure of conflict of interest in medical communities, following repeated scientific frauds in clinical trials. However, incomplete COI statements continue to be prevalent in the medical community, as appears to have occurred in the Capecitabine for Residual Cancer as Adjuvant Therapy (CREATE-X) trial, which was recently published in the New England Journal of Medicine. The authors of the article did not clearly report the roles of the Japan Breast Cancer Research Group, a sponsor and funder of the study, although a majority of the Japanese authors served in important positions in the organization. Furthermore, the conflict of interest related to Chugai Pharmaceutical Company, a Japanese distributor of capecitabine, was not correctly disclosed. More transparent statements of conflict of interest and clarification of sponsors and funders' roles, as well as rigorous review by academic journals are required to fairly interpret the findings of clinical trials, including and beyond the single case of the CREATE-X trial. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 3 | 23% |
| United States | 2 | 15% |
| Unknown | 8 | 62% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 85% |
| Scientists | 2 | 15% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 13% |
| Student > Postgraduate | 2 | 9% |
| Student > Master | 2 | 9% |
| Other | 1 | 4% |
| Librarian | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 11 | 48% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 30% |
| Social Sciences | 2 | 9% |
| Nursing and Health Professions | 1 | 4% |
| Unknown | 13 | 57% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 May 2020.
All research outputs
#4,403,626
of 24,620,470 outputs
Outputs from Science and Engineering Ethics
#316
of 950 outputs
Outputs of similar age
#72,215
of 320,639 outputs
Outputs of similar age from Science and Engineering Ethics
#15
of 32 outputs
Altmetric has tracked 24,620,470 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 950 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.3. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,639 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.